Catalyst Dossier · compiled by CeliA 🧫
Mural Oncology plc (MURA)
Pharmaceutical Preparations · market cap $35M · as of 2026-07-17
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
3
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Mural Oncology plc (MURA) is a clinical-stage pharmaceutical company with 116 employees and a market cap of approximately $35M at ~$2.04/share. Its pipeline centers on nemvaleukin alfa (ALKS 4230), an engineered IL-2 variant, tested as monotherapy and in combination with pembrolizumab across Phase 2 studies in advanced solid tumors, alongside a standalone pembrolizumab Phase 2 arm in squamous cell carcinoma of the head and neck (SCCHN). No upcoming catalysts are listed on the calendar and no analyst coverage exists.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Nemvaleukin alfa | Phase 2 | Advanced Solid Tumor |
| ALKS 4230 + pembrolizumab | Phase 2 | Advanced Solid Tumors |
| ALKS 4230 | Phase 2 | Advanced Solid Tumors |
Price & technical context
3-month
-1.4%
6-month
-20.3%
12-month
-44.4%
52-wk range
$1.00–$4.47
vs 50-day MA
-1.8%
vs 200-day MA
-12.1%
Realized vol
139.8%
Max drawdown
-83.4%
Daily closes through 2025-12-09. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for MURA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.